A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder

Name: A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
Creator: Vivli
Published: 2025-05-01 01:02:04
License: 暂无描述

DataCite Commons2025-05-01 更新2026-05-07 收录

下载链接：

https://search.vivli.org/doiLanding/studies/PR00010594/isLanding

下载链接

链接失效反馈

官方服务：

资源简介：

The study is intended to test efficacy, safety and tolerability of two doses of once daily (qd) Mirabegron against placebo to treat patients with symptoms of overactive bladder.

提供机构：

Vivli

创建时间：

2024-10-10